Mesoblast Limited (MESO) - News Archive

Pioneering Discussions: Mesoblast Poised for FDA Meeting on Rexlemestrocel-L and Opioid CessationIn a significant step towards revolutionising pain management, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global frontr...

Mesoblast Achieves Strategic Milestone: Cell Therapy Products Secure U.S. Origin Designation Amidst Industry Challenges Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a pioneering force in the development of allogeneic cellu...

: In a noteworthy advancement for the field of regenerative medicine, Mesoblast Ltd has expanded payer coverage for its pioneering therapy, Ryoncil (remestemcel-L), to over 104 million U.S. lives. Despite this significa...

Mesoblast s Strategic Advancement: U.S. Tariff Exemption and Medical Designations Propel Innovative Cell Therapies New York, April 03, 2025 In a dual win for Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global frontrunne...

Mesoblast Advances Plans for Revascor in Ischemic Heart Failure: Exploring Accelerated Approval with FDAIn a significant development for the biopharmaceutical sector, Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global l...

On March 26, 2025, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a recognized global leader in allogeneic cellular therapies aimed at treating inflammatory diseases, announced the launch of Ryoncil (remestemcel-L) in the...

In a groundbreaking development for the field of regenerative medicine, Mesoblast Limited has announced the FDA approval of RYONCIL (remestemcel-L), marking a significant milestone as the first-ever mesenchymal stromal...

New York, Sept. 29, 2024 Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines aimed at treating inflammatory diseases, has announced a pivotal new financing agreement. The biotechno...

:This article discusses the recent acceptance of Mesoblast s Biologics License Application (BLA) by the US Food and Drug Administration (FDA) for the use of Ryoncil in the treatment of children with steroid-refractory a...

Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, has recently made significant strides in its development of innovative treatments. The company announced the commencement of...

Mesoblast Ltd, a leading biotechnology company, has been a rollercoaster ride for investors this year. While the stock has outperformed the market, recent events and financial indicators raise questions about its fluctu...

The United States Food & Drug Administration (FDA) has recently notified Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, that the available clinical data from its Phase 3 t...

Mesoblast Partners With BMT CTN on Pivotal Trial for Adults With SR-aGVHDIn an exciting development for the treatment of inflammatory diseases, Mesoblast Limited has announced its partnership with the Blood and Marrow T...